Navigation Links
Novartis to Acquire Majority Stake in Hard to Treat Diseases' (HTDS.PK) China Subsidiary H1N1 Vaccine Partner for US$125 Million
Date:11/9/2009

SHENZHEN, China, Nov. 9 /PRNewswire-FirstCall/ - Hard To Treat Diseases (HTDS.PK) www.htdsmedical.com, announced today that Novartis, a US$41 billion international healthcare company, is acquiring an 85% stake in HTDS' H1N1 Vaccine partner, Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd., for US$125 million. Novartis of Switzerland will begin a five-year, $1 billion China initiative with two aims: the company will dramatically increase its investment in its China R&D facility, and it will seek to make China one its top three markets worldwide. The comments were made by Novartis' CEO, Daniel Vasella, in an interview with The Wall Street Journal. http://www.chinabiotoday.com/articles/20091103_1

HTDS' Chinese subsidiary, Mellow Hope, is the exclusive agent of Zhejiang Tianyuan Bio-pharmaceutical for International marketing and sales. Zhejiang Tianyuan Bio-pharmaceutical has been granted a H1N1 license on September 24, 2009 by the Chinese government agency, SFDA.

Terry Yuan, HTDS' President/CEO said "We believe that when you start to appreciate what Novartis' commitment to our partner in China fully means, and the see the large financial commitment to our partner just for the China market, you can begin to appreciate the enormous value to HTDS of our exclusive international marketing and sales relationship with Zhejiang Tianyuan Bio-Pharmaceutical. Further, the more you appreciate this value, the more you will find yourself understanding our value to them when they appointed us exclusive agent for international marketing and sales. As Mellow Hope owns all of registrations, clinical trials and brands for Zhejiang Tianyuan's international markets, the new Novartis-Zhejiang-Tianyuan entity will continue to leverage our assets and expertise in its international market. The Novartis purchase was announced by Novartis-Zhejiang-Tianyuan on N
'/>"/>

SOURCE Hard to Treat Diseases
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Novartis Vaccines Launches National Gift-Giving Program to Help Protect Loved Ones by Reserving an Influenza Vaccination
2. Colorado Influenza and Pneumococcal Alert Coalition (CIPAC) Partners with Novartis Vaccines for Holiday Vaccination Clinic, Making Influenza Vaccination Convenient for Shoppers
3. Novartis Vaccines Partners With RediClinic for Holiday Vaccination Clinic, Making Influenza Vaccination Convenient for Shoppers
4. Novartis Vaccines to Host Holiday Vaccination Clinic, Making Influenza Vaccination Convenient for Shoppers
5. Watson and Novartis Settle Lawsuit Over Exelon(R) Patent Litigation
6. Novartis and Sony Pictures Television Internationals Latin American Advertising Sales Group Launch Partnership to Create Multi-Media Platform for Breast Cancer Awareness, Detection, and Treatment in Latin America
7. Emerging Combination Therapies, Including Drugs from Novartis/Schering-Plough and GlaxoSmithKline/Theravance Will Drive the COPD Drug Market to More Than $11 Billion in 2017
8. Novartis, Pfizer and Merck Take the Lead on Strong Relationships with Physicians, as Doctors Demand an Expanding Set of Services
9. Novartis Pharmaceuticals Corporation to Appeal Judgment in Alabama Pricing Case
10. Novartis Makes Accessing Prescription Assistance and Disease Management Programs Simpler and Easier for Patients
11. Mylan Announces Settlement Agreement with Novartis Related to Femara(R) First- to-File Opportunity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/28/2014)... November 28, 2014 Dr. Paul Vitenas, one of ... a Glitter & Glow Holiday Event for those in the area ... at his practice. Glitter & Glow will take place on December ... new location in the heart of Houston at 4208 Richmond Ave. ... and hope that you will come and celebrate the season with ...
(Date:11/28/2014)... Celebration can quickly turn to tragedy if popular turkey ... Over the last decade, more than 141 serious fires ... turkey fryers, according to the U.S. Consumer Product Safety ... who tried to deep fry the turkey indoors, which ... Arthur Sanford, a burn surgeon at Loyola University Health ...
(Date:11/28/2014)... PreDiabetes Centers , a ... employees learn their risk for type 2 diabetes ... a local school in partnership with the American ... , As the Presenting Sponsor for the ... is co-hosting diabetes-prevention presentations at Austin-area companies with ...
(Date:11/28/2014)... (PRWEB) November 28, 2014 More ... have now been filed in a New Jersey ... implants, Bernstein Liebhard LLP reports. , A ... County Superior Court reflects the filing of 2,160 ... hip stems, which were voluntarily recalled on July ...
(Date:11/28/2014)... 28, 2014 Patten Pecans, based in ... With those passions driving them, they've added a pecan ... tried other pecans oils, they've found this pecan ... be exceptionally flavorful, retaining the buttery pecan notes that ... nutritional benefits found in pecans nuts is found ...
Breaking Medicine News(10 mins):Health News:Cosmetic Surgeon Dr. Paul Vitenas to Host Glitter & Glow Holiday Event 2Health News:Cosmetic Surgeon Dr. Paul Vitenas to Host Glitter & Glow Holiday Event 3Health News:Turkey Fryer Mishaps Can Cause Serious Burns 2Health News:PreDiabetes Centers Offers Workplace Diabetes Screening at Local School 2Health News:More than 2,100 Stryker Hip Lawsuits Included in New Jersey Litigation after Settlement Announcement, Bernstein Liebhard LLP Reports 2Health News:More than 2,100 Stryker Hip Lawsuits Included in New Jersey Litigation after Settlement Announcement, Bernstein Liebhard LLP Reports 3Health News:Patten Pecans Goes Local with Nutritious Georgia Pecan Oil 2
... older we get, the ,more difficulty we seem to have remembering ... each morning, but unless we park in the ,same space each ... whether we left the SUV in the second or fifth row. ... and will have forgotten ,their names before the handshake is over. ...
... - 13 May 2011 Elsevier, the world,s ... announced today that Syngene, India,s first contract research ... provide unlimited access to Reaxys for all Syngene ... competitiveness and productivity in the ever-expanding and highly ...
... , FRIDAY, May 13 (HealthDay News) -- A common ... the development of life-threatening heart arrhythmias (when the heart ... a new study. In pinpointing this gene, ... help doctors determine which patients are likely to benefit ...
... Lombard, IL, May 13, 2011 Dynamic chest ... compression has been well studied in events such ... not been studied during chiropractic manipulation. In a ... of Manipulative and Physiological Therapeutics , researchers quantified ...
... Ga. In a time of transition for rural ... them stay focused on their goals and avoid potential ... an ongoing University of Georgia study., The study, published ... of Community Psychology, is part of a broader ...
... New data offer hints to why Parkinson,s disease so ... say researchers at Washington University School of Medicine in ... communications including the signals that control movement. As Parkinson,s ... problems moving and other symptoms. The new research ...
Cached Medicine News:Health News:As time goes by, it gets tougher to 'just remember this' 2Health News:As time goes by, it gets tougher to 'just remember this' 3Health News:Gene Variant Linked to Sudden Cardiac Death Risk in Blacks 2Health News:Chiropractic manipulation results in little or no risk of chest injury 2Health News:Study finds youth-mentor relationships particularly helpful for those experiencing hardship 2Health News:Disruption of nerve cell supply chain may contribute to Parkinson's 2Health News:Disruption of nerve cell supply chain may contribute to Parkinson's 3
(Date:11/26/2014)... 25, 2014  goBalto, Inc., the leading provider of ... a winner of Red Herring,s Top 100 Global ... North America award in 2013, marking its emergence as ... Red Herring,s Top 100 Global list has become ... and entrepreneurs. Red Herring editors were among the first ...
(Date:11/26/2014)...   Heska Corporation (NASDAQ: HSKA ) ... of advanced veterinary diagnostic and other specialty veterinary products ... will attend The Benchmark Company, LLC,s Micro Cap Discovery Conference ... held at The Palmer House Hilton, 17 E. Monroe Street, ... 2:30 p.m. Please email hska@haydenir.com or contact your ...
(Date:11/26/2014)... LONDON , Nov. 25, 2014 ... AZN ) today announced that AMAGINE-2 TM , a ... in more than 1,800 patients with moderate-to-severe plaque psoriasis, met ... (ustekinumab) and placebo at week 12. Brodalumab 210 mg given ... each shown to be superior to Stelara on the primary ...
Breaking Medicine Technology:goBalto Selected as a 2014 Red Herring Top 100 Global Company 2goBalto Selected as a 2014 Red Herring Top 100 Global Company 3Heska to Attend Benchmark Micro Cap Discovery Conference 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 3Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 5Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 6Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 7Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 8Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 9Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 10
5 inch (12.7 cm), 2 x 5 mm blade....
Nicati foreign body spud....
In reversible handle for removing foreign bodies....
... Focus Night & Day soft contact ... to protect the cornea and to relieve ... or chronic ocular pathologies such as bullous ... corneal dystrophies as well as post-surgical conditions ...
Medicine Products: